Infected : Actualité Infected en direct - P1 | Bourse Reflex
Accueil > Tags > Infected

  • Toutes les actualités en rapport avec « Infected »

13/12 18:30 Infected - GENTICEL REPORTS FINAL RESULTS OF GTL001 PHASE 2 TRIAL IN HPV16/18-INFECTED WOMEN

08/08 18:35 Infected - Disclosure of the total number of voting rights and shares composing the share capital

08/08 18:35 Infected - HALF-YEAR SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

28/07 18:35 Infected - ACTIVITÉ DU DEUXIÈME TRIMESTRE 2016

28/07 18:35 Infected - BUSINESS UPDATE - SECOND QUARTER 2016

07/07 19:30 Infected - Disclosure of the total number of voting rights and shares composing the share capital

06/07 18:35 Infected - GENTICEL APPOINTS EUMEDIX AS STRATEGIC ADVISOR TO SUPPORT COMPANY'S ACCESS TO INNOVATIVE DRUG CANDIDATES

23/06 17:45 Infected - GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

15/06 19:30 Infected - GENTICEL TO PRESENT CLINICAL RESULTS OF GTL001 AND PRECLINICAL RESULTS OF GTL002 AT EUROGIN 2016 CONGRESS IN SALZBURG, AUSTRIA

13/06 18:35 Infected - GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

08/06 18:35 Infected - Disclosure of the total number of voting rights and shares composing the share capital

01/06 19:20 Infected - GENTICEL ANNONCE LA PUBLICATION DANS 'CLINICAL CANCER RESEARCH' DES RESULTATS DE PHASE 1 SUR L'INNOCUITE, LE PROFIL DE TOLERANCE ET L'IMMUNOGENICITE DE GTL001

01/06 19:00 Infected - GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001

11/05 08:00 Infected - Disclosure of the total number of voting rights and shares composing the share capital

28/04 18:35 Infected - BUSINESS UPDATE - FIRST QUARTER 2016

26/04 18:35 Infected - PUBLICATION OF THE 2015 ANNUAL FINANCIAL REPORT

21/04 19:45 Infected - PUBLICATION OF THE FIRST ISSUE OF GENTICEL'S SHAREHOLDER NEWSLETTER

20/04 18:30 Infected - GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

06/04 18:00 Infected - Disclosure of the total number of voting rights and shares composing the share capital

14/03 07:00 Infected - GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016